Neurogen Raises Cash, Cuts Staff
This article was originally published in The Pink Sheet Daily
Executive Summary
Lead candidate for insomnia targets “lifestyle” market, pharmacist tells “The Pink Sheet” DAILY.
You may also be interested in...
Neurogen To Try Adipiplon In Crossover Study With Ambien
Anxiety, schizophrenia studies also part of broad effort to develop GABA-based insomnia agent.
Another Hybrid License Deal: Chiesi Buys Majority Stake In Cornerstone
In a creative deal that echoes the strategic tie-up last year between Infinity and Mundipharma, Italian giant Chiesi Farmaceutici is buying a majority stake in Cornerstone Therapeutics, which gets $15.5 million along with U.S. rights for 10 years to Chiesi's marketed lung surfactant Curosurf
Another Hybrid License Deal: Chiesi Buys Majority Stake In Cornerstone
With a would-be competitor from Discovery Labs stalled at FDA, approved lung surfactant Curosurf sits at the center of equity, cash tie-up.